Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
semaglutide
Manufacturing
Experts hold line against mass compounding of GLP-1 obesity meds
The recent implosion of Novo’s team-up with telehealth firm Hims & Hers suggests there is still very much a demand for imitation weight loss drugs.
Fraiser Kansteiner
Jun 27, 2025 10:36am
GLP-1 use in diabetes linked to possible eye disease risk: study
Jun 6, 2025 7:25am
Time's up for compounders: Novo offers one-time Wegovy deal
May 22, 2025 11:26am
Madrigal's first-ever MASH drug beats sales projections again
May 2, 2025 11:00am
Novo inks Wegovy deals with telehealth companies
Apr 29, 2025 11:05am
Compounders ordered to halt production of semaglutide knockoffs
Apr 25, 2025 10:25am
